Researchers described a mass spectrometry assay that tracks patient-specific multiple myeloma M-protein peptides in plasma without requiring sequencing. In 19 myeloma patients, the assay’s longitudinal signal trends aligned with conventional monitoring approaches. The study’s premise is to identify M-protein peptides unique to each patient and then follow them over time using targeted mass spectrometry. The reported concordance with established assays suggests potential utility for labs seeking a sequencing-free workflow. If validated in larger cohorts, the approach could streamline monitoring for multiple myeloma patients by reducing turnaround time and lowering reliance on next-generation sequencing pipelines. For clinical diagnostics, the work highlights continued momentum in high-sensitivity proteomic and targeted analytical methods aimed at improving response tracking and early relapse detection.